# INmune Bio Partners With Quantum Computing Inc. to Expand XPro Treatment Uses

- URL: https://stocks.freetheai.org/news/inmune-bio-partners-with-quantum-computing-inc-to-expand-xpro-treatment-uses-7f4798
- Published: 2026-10-14T12:45:35Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:INMB](https://stocks.freetheai.org/symbols/NASDAQ-INMB)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

INmune Bio Inc. (INMB) has partnered with Quantum Computing Inc. to analyze clinical and biomedical datasets for its drug candidate, XPro. Under the collaboration, Quantum Computing Inc. will apply quantum optimization and artificial intelligence tools, including its Dirac-3S optimizer, to help identify and rank potential new disease indications.

The partnership represents an early strategic effort by INmune Bio Inc. to expand the potential uses of XPro beyond Alzheimer's disease using advanced data analytics. The move could help the company discover new therapeutic targets or pursue smaller rare-disease trials. For Quantum Computing Inc., the deal marks its first client in the pharmaceutical industry.

Investors should watch for concrete outputs from the data analysis, such as newly identified disease targets, biomarker-defined patient groups, or decisions to launch future clinical trials. The agreement also contains an option to expand the scope of work if initial findings are effective. Meanwhile, shares of INmune Bio Inc. traded down 5.62 percent to 1.68 USD following the announcement.

## Key points

- INmune Bio Inc. is using Quantum Computing Inc.'s quantum optimization and AI tools to analyze XPro clinical datasets.
- The collaboration aims to identify and prioritize potential new disease indications for XPro beyond Alzheimer's disease.
- The project utilizes Quantum Computing Inc.'s Dirac-3S optimizer and marks the firm's first pharmaceutical client.
- The agreement includes an option to expand the partnership if early results are successful.
- Shares of INmune Bio Inc. fell 5.62 percent to 1.68 USD.

## Questions and answers

### Why is INmune Bio partnering with Quantum Computing Inc.?

INmune Bio Inc. is using Quantum Computing Inc.'s quantum optimization and AI technology to analyze clinical and biomedical datasets to discover and prioritize new disease uses for its XPro candidate.

### What technology is being used in the INmune Bio collaboration?

Quantum Computing Inc. is applying quantum optimization and artificial intelligence, including its Dirac-3S optimizer, to process XPro clinical data.

### What will determine the success of this collaboration?

Key indicators of success will include concrete outcomes such as newly identified disease indications, biomarker-defined patient cohorts, or decisions to start new clinical trials.